

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Maciej Kusmierczuk

Page 1/2

Tuesday, June 06, 2023

## SPEAKERS' CORNER

### 15:30 – 16:45 **Update on innovations, clinical trials and new data – treatment of femoropopliteal PAD I – part I**

*MODERATOR:*

Ralf Langhoff

*MODERATOR:*

Lieven Maene

15:30 – 15:35 2-year clinical outcome of the Eluvia drug-eluting stent for femoropopliteal lesions: A prospective multicenter K-ELUVIA registry

Young-Guk Ko

15:35 – 15:40 CVT-SFA-trial: First report of 6 months results using a new Everolimus coated balloon technology

Stephan Duda

15:40 – 15:45 Performance of a novel Sirolimus eluting balloon in peripheral arterial disease: Insights from the SUCCESS PTA study

Michael Lichtenberg

15:45 – 15:50 Safety, efficacy and clinical implications of drug-coated devices in the endovascular treatment of femoropopliteal lesions

Jana Prchal

15:50 – 15:55 Comparative 2-year clinical outcomes of paclitaxel-eluting stent and drug-coated balloons in large vessels of femoropopliteal artery lesions

Masanaga Tsujimoto

15:55 – 16:00 Safety of a dual drug sirolimus and ptx coated balloon (Sirplux™ DCB) vs a commercially available PTX DCB in swine coronary arteries

Kenji Kawai

16:00 – 16:05 2-year outcome among the bare metal stent, atherectomy combined with or without drug-coated balloon angioplasty for femoropopliteal arterial occlusion

Lin Yang

16:05 – 16:10 BIOPACT RCT – subgroup analysis to assess for heterogeneity of clinical endpoints, for patients treated with Passeo-18 Lux DCB vs IN.PACT Admiral DCB for femoropopliteal lesions

Koen Deloose

16:10 – 16:15 Resorbable Repair Device (RRD) for coverage of flow limiting dissections after DCB angioplasty

**Maciej Kusmierczuk**

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Maciej Kusmierczuk

Page 2/2

## Tuesday, June 06, 2023

- |               |   |
|---------------|---|
| 16:15 – 16:20 | Vascular effects through Sirolimus vs. Paclitaxel DCB treatment in symptomatic peripheral artery disease – the Limus FLOW investigator-initiated randomized controlled trial<br>Christos Rammos |
| 16:20 – 16:25 | Analysis about the frequency of distal emboli due to three kinds of Paclitaxel-coated balloon in femoropopliteal artery using a laser doppler flowmetry<br>Kuniyoshi Fukai                      |
| 16:25 – 16:30 | A case of virtual PQ bypass using double snare-piercing technique<br>Shuhei Uchida  |
| 16:30 – 16:45 | Discussion and conclusion<br>Ralf Langhoff<br>Lieven Maene  |

We are asking all faculty members to strictly respect the given time limits.